Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
Novel biological therapies for managing non-Hodgkin lymphoma
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
BTK inhibitors for relapsed mantle cell lymphoma: the new standard of care?
The importance of recgonizing different DLBCL subtypes